Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma

NCT06435273 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06435273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06435273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
August 5, 2024
Completion date
October 15, 2025
Enrollment
36 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

asthma